New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
23:38 EDTJCP, CSCO, HPY, PETM, LMT, AMGN, HDJim Cramer's "Mad Money"
Cramer said it's downright infuriating, just when the housing market was beginning to recover, autos were getting stronger, retail sales were growing and banks looked like they were finally finding their footing, Congress has been able to undo it all and send our markets sharply lower. We're now facing the first congressionally mandated bear market we've ever seen, said Cramer, all because 536 people couldn't agree. For the year, U.S. stocks are now up just half of their counterparts in Europe, and Europe is in a recession. Cramer came up with three indicators to help investors figure out whether the effects of the fiscal cliff are baked into the markets and whether its time to begin buying back in. First: "Washington on TV" indicator. Anytime the president or member of Congress gets on the air, expect the markets to go lower. Second: Lockheed Martin (LMT), the defense contractor with a 5% dividend yield. If the U.S. falls over the fiscal cliff, Lockheed will get hurt by both defense spending cuts and a rise in dividend taxes, Cramer noted, making this stock uniquely positioned to feel the blow. Third: Investors can use Cisco (CSCO), Home Depot (HD) and Petsmart (PETM) as gauges for Washington's damage. Cramer said all three of these companies posted stellar earnings, so if they can't hold onto their gains, no one can. SELL BLOCK: Cramer reminded viewers some stocks go down because they deserve to, and that's certainly the case with J.C. Penney (JCP). The company remains a value trap and is showing no signs of improving. Penney has had three disappointing quarters in a row, Cramer noted, and sales still continue to decline, dramatically so, and the company's balance sheet is weakening. Then, continuing with his "Upside Surprise Party" series of stocks to buy as the markets continue to fall on fiscal cliff worries, Cramer recommended drug maker Amgen (AMGN). The company has a huge pipeline of new drugs on the way and a 1.7% yield. Trading at just 12x earnings with a 10.5% long-term growth rate, Cramer said he's never seen Amgen trade as low as it is right now. EXECUTIVE DECISION: Cramer sat down with Robert Carr, chairman and CEO of Heartland Payment Systems (HPY), our nation's fifth-largest payment processor. Heartland's most recent quarterly results included a 5c earnings beat on better-than-expected revenue with upside guidance. Cramer continued his recommendation and said Heartland Payment Systems is a great story. NO HUDDLE OFFENSE: Cramer offered his quick "Top 5" reasons why they shouldn't be sellers in Friday's market. First: stocks are already very oversold -- there will be a better time to sell later. Second: while many stocks will be impacted by the fiscal cliff, others, like international names, will not, which is why it's prudent to buy, not sell, into weakness. Third: everything gets baked into stock prices eventually, and stocks often bottom before big events occur, not after. Fourth: the higher taxes and spending cuts of the fiscal cliff won't be the end of the world for certain sectors, like health care and those that offer consumers a bargain. And, Fifth: companies with big dividends will likely be able to raise those dividends to cover, at least partially, any higher tax rates from the fiscal cliff. Reference Link
News For LMT;CSCO;HD;PETM;JCP;AMGN;HPY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 9, 2014
10:01 EDTLMTNorthrop Grumman selected by Lockheed Martin to supply navigation system
Subscribe for More Information
08:19 EDTCSCOCisco outlook has improved, says RBC Capital
RBC Capital believes that Cisco's negative catalysts are diminishing. The firm thinks the stock is being boosted by its successful efforts to keep its gross margin at or above the 61%-62% range, as well as a rebound in its switching business. RBC recommends buying the stock on dips and keeps a $29 price target and Outperform rating on the name.
07:44 EDTAMGNAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:41 EDTCSCOBarclays to hold a conference
Global Technology Conference is being held in San Francisco on December 9-10 with webcasted company presentations to begin on December 9 at 10:40 am; not all company presentations may be webcasted. Webcast Link
06:39 EDTCSCOCisco initiated with an Outperform at Wedbush
Subscribe for More Information
05:40 EDTAMGNAmgen presents new BLINCYTO Phase 2 study data at ASH meeting
Amgen announced that new data from a pivotal Phase 2 study evaluating BLINCYTO for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, or ALL was presented at the 56th American Society of Hematology, or ASH, Annual Meeting and Exposition. In one analysis from the '211 study, 40% of patients treated with BLINCYTO who achieved a complete remission, or CR, or complete remission with partial hematologic recovery, or CRh, were enabled to proceed to allogeneic hematopoietic stem cell transplant, or HSCT. Additionally, a secondary analysis from the study found that 82% of patients who had a CR or CRh also had a minimal residual disease, or MRD, response, a measure used to predict disease recurrence in patients with ALL. In one analysis of the '211 study, 40% of patients treated with BLINCYTO who achieved a CR or CRh were enabled to proceed to HSCT, including both patients who had received prior HSCT and patients who had not received prior HSCT. A secondary analysis of the study demonstrated that, among patients receiving BLINCYTO who had a CR or CRh and had evaluable MRD data, 82% had an MRD response, with 70% of those patients achieving a complete MRD response. Median overall survival was longer among patients who had a CR or CRh and an MRD response compared to patients who didn't have an MRD response.
December 8, 2014
16:24 EDTAMGNAmgen initiates new combination trial for talimogene laherparepvec with KEYTRUDA
Subscribe for More Information
12:40 EDTCSCOUS Supreme Court to hear appeal in patent fight with Cisco
The U.S. Supreme Court has agreed to hear an appeal of a controversial appeals court decision that set aside a $63.8M patent infringement verdict won by The Woodlands, Texas-based Commil USA LLC against Cisco
09:09 EDTAMGNAmgen announces FDA approval for XGEVA
Amgen announced that the FDA has approved a new indication for XGEVA for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. XGEVA was approved and granted Orphan Drug Designation by the FDA, which is reserved for drugs that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S. HCM is a serious complication in patients with advanced cancer, including those with hematologic malignancies, and indicates poor prognosis.1,2 The condition results from cancer-driven increases in bone resorption, and if untreated, can lead to renal failure, progressive mental impairment, coma and death. The approval of XGEVA is based on positive results from an open-label, single-arm study, which enrolled patients with advanced cancer and persistent hypercalcemia after recent bisphosphonate treatment. The primary endpoint was the proportion of patients with a response, defined as albumin-corrected serum calcium <11.5 mg/dLwithin 10 days after the first dose of XGEVA. Secondary endpoints included the proportion of patients who experienced a complete response (defined as CSC <10.8 mg/dL by day 10, time to response and response duration. The study achieved its primary endpoint with a response rate at day 10 of 63.6 percent in the 33 patients evaluated. The overall complete response rate was 63.6 percent. The estimated median time to response was nine days, and the median duration of response was 104 days.4,5
09:09 EDTAMGNAmgen announces FDA approval for XGEVA
Subscribe for More Information
08:40 EDTCSCODeutsche Bank and Cisco to host a conference call
Subscribe for More Information
08:02 EDTCSCOAruba says NHS replaces Cisco network with Aruba wireless infrastructure
Subscribe for More Information
07:49 EDTCSCOArista Networks lawsuit not as threatening as believed, says SunTrust
Subscribe for More Information
07:32 EDTCSCORaymond James to hold a conference
Subscribe for More Information
07:03 EDTCSCOArista Networks patent resolution likely 2-3 years away, says Citigroup
Subscribe for More Information
06:21 EDTPETMDeadline for Petsmart bidders extended as lenders put on leash, NY Post reports
Subscribe for More Information
05:42 EDTAMGNSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
December 7, 2014
14:38 EDTAMGNAmgen announces new data from Phase 2 BLINCYTO immunotherapy study
Amgen announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager, BiTE, immunotherapy BLINCYTO in patients with minimal residual disease, MRD, positive B-cell precursor acute lymphoblastic leukemia, ALL. In the study, 78% of patients who received BLINCYTO experienced a complete MRD response , a measure of eradication of residual disease at the molecular level, after one treatment cycle. Nearly all complete responses occurred within the first treatment cycle. The results from the BLAST study will be featured during the 56th American Society of Hematology Annual Meeting and Exposition press briefing on Saturday, December 6, at 10 a.m. PT and will be presented in an oral session at ASH on Monday, December 8, at 10:30 a.m. PT. "BLINCYTO is the most advanced of Amgen's BiTE immunotherapies, a new and innovative approach that helps the body's own immune system fight cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Achieving molecular complete remission is an important goal in the treatment of ALL, and the data presented at ASH demonstrates that BLINCYTO can produce deep responses in patients that have trace amounts of residual disease." MRD is a state of disease in which the microscopic analysis does not show malignant cells, but more sensitive techniques still detect disease at the molecular level. Patients who have persistent or recurrent MRD after their first therapy have a higher risk of relapse than those with no detectable MRD. In addition to the majority of patients achieving a compete MRD response within one cycle of treatment, 80% achieved a complete MRD response across all cycles. Responses occurred in all subgroups including older patients and patients with high MRD level; no predictive factor for MRD response was identified. In the study, adverse events of all grades occurring in 20% or more patients included pyrexia, tremor, chills, fatigue, nausea, vomiting and diarrhea. Grade =3 AEs occurring in five percent or more patients included neutropenia , pyrexia and tremor. Two fatal AEs occurred on treatment: subdural hemorrhage and pneumonitis in conjunction with influenza. Treatment interruptions due to AEs occurred in 31% of patients.
14:18 EDTAMGNAmgen, Onyx announce detailed results from Phase 3 ASPIRE study of Kyprolis
Subscribe for More Information
14:10 EDTAMGNAmerican Society of Hematology to hold a meeting
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use